MAPK/ERK Signaling Pathway in Neurodegeneration

MAPK/ERK Signaling Pathway in Neurodegeneration

Introduction

The Mitogen-Activated Protein Kinase (MAPK)/Extracellular Signal-Regulated Kinase (ERK) pathway is a central signaling cascade that transduces extracellular signals into cellular responses. Originally characterized in the context of cell proliferation and differentiation, this pathway plays critical roles in neuronal differentiation, synaptic plasticity, learning and memory, and neuronal survival. Dysregulation of MAPK/ERK signaling contributes to the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders. [@thomas2004]

Pathway Architecture

MAPK Cascade

The MAPK/ERK pathway consists of a three-tier kinase cascade: [@giovannini2002]

Growth Factor → RTK → Ras → Raf → MEK1/2 → ERK1/2 → Nuclear Targets

| Kinase | Alternative Names | Function |
|--------|-------------------|----------|
| Ras | HRAS, KRAS, NRAS | Small GTPase, molecular switch |
| Raf | ARAF, BRAF, RAF1 | MAPKKK, activates MEK |
| MEK1/2 | MAP2K1, MAP2K2 | MAPKK, activates ERK |
| ERK1/2 | MAPK1 (ERK2), MAPK3 (ERK1) | MAPK, nuclear targets |

Upstream Activators

• Growth factors: BDNF, NGF, EGF, IGF-1
• Neurotransmitters: Glutamate (via NMDA receptors), dopamine
• Cell adhesion molecules: Integrins
• Stress: Oxidative stress, ER stress

Nuclear Targets

Once activated, ERK1/2 translocates to the nucleus and phosphorylates:

• Transcription factors: CREB, ELK-1, c-Fos, c-Myc
• Chromatin modifiers: Histone H3
• Other kinases: MSK1/2, MNK1/2

MAPK/ERK Signaling Pathway in Neurodegeneration

Introduction

The Mitogen-Activated Protein Kinase (MAPK)/Extracellular Signal-Regulated Kinase (ERK) pathway is a central signaling cascade that transduces extracellular signals into cellular responses. Originally characterized in the context of cell proliferation and differentiation, this pathway plays critical roles in neuronal differentiation, synaptic plasticity, learning and memory, and neuronal survival. Dysregulation of MAPK/ERK signaling contributes to the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders. [@thomas2004]

Pathway Architecture

MAPK Cascade

The MAPK/ERK pathway consists of a three-tier kinase cascade: [@giovannini2002]

Growth Factor → RTK → Ras → Raf → MEK1/2 → ERK1/2 → Nuclear Targets

| Kinase | Alternative Names | Function |
|--------|-------------------|----------|
| Ras | HRAS, KRAS, NRAS | Small GTPase, molecular switch |
| Raf | ARAF, BRAF, RAF1 | MAPKKK, activates MEK |
| MEK1/2 | MAP2K1, MAP2K2 | MAPKK, activates ERK |
| ERK1/2 | MAPK1 (ERK2), MAPK3 (ERK1) | MAPK, nuclear targets |

Upstream Activators

• Growth factors: BDNF, NGF, EGF, IGF-1
• Neurotransmitters: Glutamate (via NMDA receptors), dopamine
• Cell adhesion molecules: Integrins
• Stress: Oxidative stress, ER stress

Nuclear Targets

Once activated, ERK1/2 translocates to the nucleus and phosphorylates:

• Transcription factors: CREB, ELK-1, c-Fos, c-Myc
• Chromatin modifiers: Histone H3
• Other kinases: MSK1/2, MNK1/2

MAPK/ERK in Alzheimer's Disease

Synaptic Plasticity and Memory

ERK signaling is required for long-term potentiation (LTP), the cellular basis of learning and memory. NMDA receptor activation leads to Ras-ERK signaling, which is necessary for AMPA receptor trafficking and synaptic strengthening. In AD, Aβ oligomers impair ERK activation, contributing to synaptic failure. [@zhang2023]

Tau Pathology

ERK can phosphorylate tau at multiple sites (Thr181, Ser202, Thr231, Ser396). While ERK-mediated tau phosphorylation may be protective under normal conditions, dysregulated ERK activation in AD contributes to pathological tau hyperphosphorylation and aggregation. [@crowther2005]

Neuronal Survival

ERK signaling promotes neuronal survival through phosphorylation of pro-survival targets. However, in AD, the pathway is often impaired, reducing neuroprotective signaling. [@kim2010]

Aβ Production

ERK can regulate amyloid precursor protein (APP) processing and Aβ production. ERK activation may increase BACE1 expression, potentially accelerating Aβ generation. [@veeranna2000]

MAPK/ERK in Parkinson's Disease

Dopaminergic Neuron Survival

ERK signaling is required for development and survival of dopaminergic neurons. In PD, impaired ERK signaling contributes to neuronal vulnerability. However, the role is complex—ERK can be protective or detrimental depending on context. [@sharrocks2001]

α-Synuclein Toxicity

ERK activation is observed in PD brains and model systems. α-Synuclein can both activate and be regulated by MAPK pathways. Sustained ERK activation may contribute to neuronal dysfunction.

Mitochondrial Dysfunction

ERK can regulate mitochondrial function through phosphorylation of mitochondrial proteins. Impaired ERK signaling contributes to mitochondrial dysfunction in PD.

Neuroinflammation

ERK in microglia drives production of pro-inflammatory cytokines. ERK activation in glia contributes to chronic neuroinflammation in PD.

MAPK/ERK in Other Neurodegenerative Diseases

ALS

ERK activation is observed in motor neurons and glia in ALS. The pathway may have dual roles—contributing to inflammation while also promoting survival signaling.

Huntington's Disease

ERK signaling is dysregulated in HD. Both reduced and aberrant ERK activation have been reported, contributing to transcriptional dysfunction and neuronal death. [@taylor2015]

Therapeutic Implications

MAPK Pathway Inhibitors

| Drug | Target | Clinical Use | Status in Neurodegeneration |
|------|--------|--------------|----------------------------|
| Selumetinib | MEK1/2 | Approved (cancer) | Preclinical |
| Trametinib | MEK1/2 | Approved (cancer) | Preclinical |
| Cobimetinib | MEK1/2 | Approved (cancer) | Preclinical |
| PD98059 | MEK1 | Research tool | Preclinical |
| U0126 | MEK1/2 | Research tool | Preclinical |

Challenges

• Complex, context-dependent effects
• Blood-brain barrier penetration
• Balancing beneficial vs. detrimental effects
• Timing of intervention critical

Cross-Links

• See also: [Synaptic Dysfunction Pathway](/mechanisms/synaptic-dysfunction-pathway) — ERK in LTP
• See also: [BDNF Signaling](/mechanisms/bdnf-neurotrophin-signaling-pathway) — Upstream activator
• See also: [Tau Pathology Pathway](/mechanisms/tau-pathology-pathway) — ERK-mediated tau phosphorylation
• See also: [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway) — Microglial ERK activation
• See also: [CREB Signaling](/mechanisms/creb-signaling-memory) — Downstream target

Mermaid Diagram: MAPK/ERK in Neurodegeneration

Confidence Assessment

🟡 Moderate Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 15 references |
| Replication | Multiple studies |
| Effect Sizes | Context-dependent |
| Contradicting Evidence | Some |
| Mechanistic Completeness | 60% |

Overall Confidence: 50%

References

Pathway Diagram

The following diagram shows the key molecular relationships involving MAPK/ERK Signaling Pathway in Neurodegeneration discovered through SciDEX knowledge graph analysis: